SureTrader SureTrader Nadex Advertisement SureTrader
Home > Boards > US OTC > Medical - Drugs >

Entest BioMedical Inc. (ENTB)

ENTB RSS Feed
Add ENTB Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 2/16/2017 11:54:18 AM - Followers: 444 - Board type: Free - Posts Today: 0

                                     ENTB LATEST NEWS FROM JUNE 1, 2016:
http://www.barchart.com/headlines/story/8402740/entest-biomedical-inc-in-discussions-to-acquire-nanotechnology-delivery-system-for-cancer-therapy




 

http://www.entb.net


 

 

 

 

 

Company Information:                                                      
4700 Spring Street, Suite 304
La Mesa, Calif. 91942
Telephone: 619-644-3344
Fax: 619-330-2328
E-mail:
info@EntestBio.com

Web site: www.EntestBio.com

 

CIK 0001449447
 

ImenVax (TM)

Immuno-Therapeutic Cancer Treatment for Canines


 

In the encapsulated ImenVax™ device, a "cocktail" of integral immuno-catalysts are enclosed. From this ImenVax™ device immuno-catalysts are released which activate the patient's immune cell. These immune cells carry on their normal course of activity by entering the lymph nodes and cause T-Cell adaptation. These T-Cells are what attack and kill the tumor. (Figure 1)
 


Entest BioMedical Inc. (OTCQB: ENTB)is a majority owned subsidiary of Bio-Matrix Scientific Group Inc (OTCQB: BMSN). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), cancer immuno-therapies, testing procedures for diabetes and stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).

Currently, Entest is focused on research and development in areas of COPD and Immuno-Therapeutic Cancer Vaccines. The Company sees applications for its patent pending technologies in both human and animal venues.

Immuno-therapeutic treatment of cancer - The patent pending Entest application involves perfecting the use of cell lines for sustained release of immunologically relevant cytokines for maximum anti-tumor immune responses in treating cancer. The treatment process itself will utilize an implantable encapsulation device as the vaccine delivery system and the initial focus will be treatment of cancer in canines. This canine cancer treatment may also provide clinical support for expansion into human cancer treatment.

Chronic Obstructive Pulmonary Disease -There is currently no cure for COPD and therapy is limited to management of the condition and its symptoms. Over the next 5 years, it is estimated that over $170 billion will be spent on treating COPD in the United States. Entest believes its COPD treatment, which utilizes patent pending adult stem cell therapy coupled with photoceutical device enhancement, has the potential to reverse COPD related lung damage as well as alleviate symptoms.

Entest BioMedical was founded for the purpose of providing excellence in biotechnology research (including adult stem cell regenerative treatment). Our objectives go beyond developing single products and procedures. Our mission is to discover and develop new procedures, treatments and medical devices that improve the quality of life. Our efforts revolve around a business focus of developing leading research and technology. Ongoing R&D is paramount to us in developing products and procedures with purpose, products and services that serve the present and help shape the future.

 

Management: 

David R. Koos, PhD, DBA - Chairman and CEO, Secretary, Acting CFO
Feng Lin, MD, PhD - Director of Research
Marilyn Panahi - Director of Quality Assurance



 

 

http://www.entb.net
 

 Recent News!

June 1, 2015

 http://www.marketwired.com/press-release/entest-biomedical-inc-discussions-acquire-nanotechnology-delivery-system-cancer-therapy-otc-pink-entb-2025182.htm

 

 

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ENTB
Current Price
Volume:
Bid Ask Day's Range
SureTrader
ENTB News: Quarterly Report (10-q) 01/11/2017 10:29:57 AM
ENTB News: Annual Report (10-k) 11/23/2016 06:08:21 AM
ENTB News: Current Report Filing (8-k) 09/26/2016 06:04:39 AM
PostSubject
#38011   Not sure where this will be then. Many JokersWild12 02/16/17 11:54:18 AM
#38010   Thanks for your thoughts.based on Zander progress lately, ronrooster 02/16/17 11:22:05 AM
#38009   The patent application is evidence that there is JokersWild12 02/16/17 11:06:50 AM
#38008   Am I correct to sumize that this release ronrooster 02/15/17 07:21:41 PM
#38007   News Entest BioMedical Inc.'s (OTCPINK: ENTB) wholly owned subsidiary, JokersWild12 02/15/17 09:26:40 AM
#38006   You have my luck! bme 02/14/17 11:56:57 PM
#38005   I'll check the calendar to see if another jeffshir 02/14/17 07:49:09 PM
#38004   Are you going to say that again next bme 02/14/17 05:59:45 PM
#38003   Massive BID again: 507,000 Kbro13 02/14/17 03:34:11 PM
#38002   Finally next week is coming jeffshir 02/10/17 04:18:46 PM
#38001   BID 30,000 0.0451 ASK 0.0539 50,000 Kbro13 02/10/17 02:59:37 PM
#38000   Would appreciate if u could post latest L2 ronrooster 02/10/17 02:47:42 PM
#37999   ENTB-35min... CDEL still counting their pennies DayTrader1963 02/10/17 11:43:18 AM
#37998   wish they would just slap the ask already, salesleader 02/10/17 10:38:51 AM
#37997   459,500 BID @ 0.045! Kbro13 02/10/17 09:37:03 AM
#37996   I like what I see. MrBrakk 02/09/17 01:18:39 PM
#37995   They are trying to slow it down with gotinearly 02/09/17 10:26:29 AM
#37994   $ENTB - Nice start again today. Kbro13 02/09/17 09:54:16 AM
#37993   $ENTB - getting jiggy. Kbro13 02/08/17 04:47:14 PM
#37992   Nice day. Kbro13 02/08/17 04:41:10 PM
#37991   Things will be moving fast as they look jeffshir 02/08/17 02:38:03 PM
#37990   Got this a little while ago salesleader 02/08/17 12:47:00 PM
#37989   Company's plan is to move rapidly on their JokersWild12 02/08/17 12:26:21 PM
#37988   Nice. 3yrs+ here for me. Kbro13 02/08/17 11:01:00 AM
#37987   Wouldn't surprise me at all, they are serious pandra 02/08/17 10:08:22 AM
#37986   $ENTB - More new this morning? Kbro13 02/08/17 09:37:45 AM
#37985   Resistance broken. Kbro13 02/08/17 09:36:22 AM
#37984   Volume and up 16.5% already! Kbro13 02/08/17 09:34:15 AM
#37983   LOL... so much boom .... h13alino 02/07/17 04:05:04 PM
#37982   Nope gotinearly 02/06/17 10:53:42 PM
#37981   Will someone report David Koos to the SEC? Fitzgerald 02/06/17 06:30:18 PM
#37980   Thanks.GLTU and all ENTB longs. ronrooster 02/06/17 05:37:35 PM
#37979   Awesome volume today! Good to see the management JokersWild12 02/06/17 05:35:20 PM
#37978   Just a thought re ENTB news today.unusual for ronrooster 02/06/17 03:59:11 PM
#37977   ???? h13alino 02/06/17 03:28:43 PM
#37976   $ENTB starting up .. Unlimited~OTC 02/06/17 02:30:00 PM
#37975   Lol ..... just kidding ? h13alino 02/06/17 02:09:38 PM
#37974   Yessss! Boom!!! MrBrakk 02/06/17 12:48:25 PM
#37973   Boooom .... LOL ! h13alino 02/06/17 12:35:04 PM
#37972   Boooom ????? h13alino 02/06/17 12:05:28 PM
#37971   BOOOOOOOMMMMMM!!!!!! gotinearly 02/06/17 10:28:02 AM
#37970   News 2/6/17 JokersWild12 02/06/17 09:18:57 AM
#37969   Progressing News For Regen which will translate to ENTEST(Zander): JokersWild12 02/01/17 11:17:30 AM
#37968   agreed salesleader 01/30/17 11:34:39 AM
#37967   $ENTB - Coiled and ready for next jump Kbro13 01/27/17 10:55:38 AM
#37966   Thanks Ronrooster. Hopefully the float stays the same. JokersWild12 01/26/17 03:07:30 PM
#37965   Don't forget that the Float for ENTB is ronrooster 01/26/17 01:43:42 PM
#37964   Zander website management has been updated. ronrooster 01/26/17 01:42:12 PM
#37963   The split was 1 for 150. That was JokersWild12 01/25/17 02:29:26 PM
#37962   Months ago jeffshir 01/25/17 01:44:19 PM
PostSubject